Live Breaking News & Updates on Prostate Cancer Clinical Research

Partnering up with Abiraterone Acetate – Potentials for a Harmonious Relationship
Published 03 May 2021
Abiraterone acetate has demonstrated benefit across the metastatic prostate cancer spectrum when combined or layered on conventional androgen deprivation therapy. Whether it be metastatic castration-sensitive (mCSPC) or metastatic castration-resistant prostate cancer (mCRPC) in either the pre-or the post-docetaxel setting, the overall survival benefit is certain.
1-4 Attempts to advance to the next level with additional agents added to abiraterone acetate, in the first-line mCRPC setting, have been met with mixed results. At this time, other than the continuing foundation of androgen deprivation therapy, there is no therapeutic agent regulatory approved for combination with abiraterone acetate. ....

United States , Fred Hutchinson Cancer Research Center , University Of Washington , Evan Yu , Clinical Research Division , Clinical Research Service , Prostate Cancer Clinical Research , Seattle Cancer Care Alliance , Fred Hutchinson Cancer Research Consortium , University Of Washington School Medicine , Clinical Research , Division Of Oncology , Department Of Medicine , Washington School , Clinical Research Director , Genitourinary Oncology , Medical Director , Randomized Phase , Sequential Abiraterone Acetate , Metastatic Castration Resistant Prostate Cancer , ஒன்றுபட்டது மாநிலங்களில் , ஃப்ரெட் ஹட்சின்சன் புற்றுநோய் ஆராய்ச்சி மையம் , பல்கலைக்கழகம் ஆஃப் வாஷிங்டன் , எவன் யூ , மருத்துவ ஆராய்ச்சி பிரிவு , மருத்துவ ஆராய்ச்சி சேவை ,